VivoSim Labs (NASDAQ:VIVS) Releases Quarterly Earnings Results

VivoSim Labs (NASDAQ:VIVS) released its quarterly earnings results on Thursday. The company reported ($0.03) earnings per share for the quarter, FiscalAI reports. The business had revenue of $0.05 million during the quarter. VivoSim Labs had a negative net margin of 11,016.07% and a negative return on equity of 612.23%.

VivoSim Labs Stock Down 10.8%

NASDAQ VIVS opened at $0.14 on Friday. VivoSim Labs has a 52-week low of $0.12 and a 52-week high of $3.40. The company has a fifty day moving average of $0.20 and a 200-day moving average of $1.00.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of VivoSim Labs in a report on Wednesday, August 19th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock presently has an average rating of “Sell”.

VivoSim Labs Company Profile

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds.